Starpharma Holdings Limited (ASX: SPL)
Health Care · Pharmaceuticals · AU
AU$0.80
-4.76% today · +135.3% 1Y
Starpharma Holdings Limited (ASX: SPL) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $265.14M and employs 50 people.
Over the last twelve months the share price has gained 135.3%, trading between 0.25 and 0.88.
Tweenvest scores Starpharma Holdings Limited across four factors: quality 42/100, value 63/100, growth 100/100. Its strongest factor is growth.
SPL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $265.14M
- Revenue (TTM)
- $8.76M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.72
- 52-week high
- AU$0.88
- 52-week low
- AU$0.25
- Avg volume (3M)
- —
- Shares outstanding
- 476.85M
- Employees
- 50
- Next earnings
- —
About Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
- ISIN
- AU000000SPL0
- Founded
- 1997
- Listed since
- Sep 27, 2000
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharmasaga Co. Ltd.TPEX: 7878 | $279.83M | NT$166.50 | -8.77% |
| Hikal LimitedBSE: 524735 | $279.37M | Rs218.15 | +0.09% |
| Duopharma Biotech BerhadKLSE: DPHARMA | $268.43M | RM1.14 | -4.20% |
| Guangdong Jiaying Pharmaceutical Co., LtdSZSE: 002198 | $265.31M | CN¥3.58 | -0.83% |
| Hunan Nucien Pharmaceutical Co., Ltd.SHSE: 688189 | $259.64M | CN¥6.44 | -0.62% |
| Celon Pharma S.A.WSE: CLN | $258.98M | zł18.68 | -0.11% |
| AFT Pharmaceuticals LimitedNZSE: AFT | $257.17M | NZ$4.37 | -0.46% |
| ACC Aviation Holdings Ltd.OTCPK: CAVG | $254.46M | $— | — |
Figures last refreshed Oct 4, 2026.